Profile data is unavailable for this security.
About the company
The Biotech Growth Trust PLC is a United Kingdom-based externally managed investment trust. The Company's investment objective is to seek capital appreciation through investment in the biotechnology industry across the world. It invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The Company invests more than 10%, in aggregate, of the value of its gross assets in other closed-end investment companies (including investment trusts) listed on the London Stock Exchange. The Company invests more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. Its portfolio of investments across various countries includes the Netherlands, the United States of America, Canada, and China. The Company’s alternative investment fund manager is Frostrow Capital LLP.
- Revenue in GBP (TTM)-17.22m
- Net income in GBP-21.35m
- Incorporated1997
- Employees0.00
- LocationThe Biotech Growth Trust PLC25 Southampton BuildingsLONDON WC2A 1ALUnited KingdomGBR
- Phone+44 20 3008 4910Fax+44 20 3043 8889
- Websitehttps://www.biotechgt.com/
Profile
| Management group(s) | OrbiMed Advisor LLC |
|---|---|
| AIC sector | Biotechnology & Healthcare |
| ISIN | GB0000385517 |
| Launch date | 23 Jun 1997 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | GBP |
Objective
The Company seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis.
Managed by
| Josh Golomb, Geoffrey C. Hsu |
|---|
Management & contract fees
AIFM receives a periodic fee equal to 0.30% p.a. of the market capitalisation up to GBP500m, 0.20% above GBP 500m to GBP 1bn and 0.10% over GBP 1bn. The Investment Manager receives a fee equal to 0.65% p.a. of the net assets. The Agreement may be terminated with not less than 12 months notice.
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Baillie Gifford UK Growth Trust PLC | 37.57m | 34.22m |
| Mid Wynd International Invest Trust PLC | -17.04m | -19.80m |
| B.P. Marsh & Partners plc | 117.54m | 104.43m |
| Literacy Capital PLC | 7.39m | -1.78m |
| Jpmorgan China Growth & Income PLC | 49.53m | 46.02m |
| Schroder Income Growth Fund PLC | 23.79m | 20.37m |
| Schroder UK Mid Cap Fund PLC | 28.93m | 25.29m |
| Sherborne Investors (Guernsey) C Ltd | -42.58m | -43.43m |
| Biotech Growth Trust PLC | -17.22m | -21.35m |
| Pembroke VCT PLC | 9.00m | 3.11m |
| Odyssean Investment Trust PLC | 320.00k | -2.09m |
| Abrdn UK Smlr Cmpn Grth Trst PLC | 22.86m | 17.14m |
| Albion Technology & General VCT PLC | 5.45m | 109.00k |
| Albion Enterprise VCT PLC | 9.64m | 3.21m |
| Brooks Macdonald Group plc | 111.56m | 11.63m |
| Fintel PLC | 85.00m | 6.20m |
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
| Rathbones Investment Management Ltd.as of 31 Mar 2025 | 2.06m | 9.78% |
| Brewin Dolphin Ltd.as of 31 Mar 2025 | 1.78m | 8.44% |
| Hargreaves Lansdown Fund Managers Ltd.as of 01 Oct 2025 | 1.09m | 5.17% |
| TrinityBridge Ltd.as of 01 Oct 2025 | 416.00k | 1.97% |
| Aviva Investors Global Services Ltd.as of 01 Oct 2025 | 387.00k | 1.84% |
| BlackRock Investment Management (UK) Ltd.as of 01 Oct 2025 | 254.09k | 1.21% |
| UBS Asset Management (Americas) LLCas of 01 Oct 2025 | 237.00k | 1.13% |
| Unicorn Asset Management Ltd.as of 01 Oct 2025 | 200.00k | 0.95% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Oct 2025 | 174.00k | 0.83% |
| JPMorgan Asset Management (UK) Ltd.as of 01 Oct 2025 | 162.56k | 0.77% |
